BCAB — BioAtla, Inc.
$1.55
$-0.10 (-6.06%)
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma.
Market Cap
$2.59M
Forward P/E
-1.2x
52-Week Range
N/A
BCAB Price History
Revenue vs. Net Income
$11M
Revenue · FY2024
Annual. Net margin is shown under each year.
Free Cash Flow
-$71.9M
FCF · FY2024
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-195.2%
ROCE · FY2024
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.4x
Assets ÷ liabilities · FY2024
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
369.6%
CapEx · FY2021
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+21.6%
Dilution · FY2024
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
